Full Article

M Kozloff

Hong Kong J Radiol 2011;14(Suppl):S4-11

Bevacizumab is one of the novel pharmacological agents used for the treatment of multiple tumour types including metastatic colorectal cancer, non–small-cell lung cancer, metastatic breast cancer, glioblastoma multiforme, and metastatic renal carcinoma.

Full Article

KF Tam

Hong Kong J Radiol 2011;14(Suppl):S19-23

Most patients with ovarian cancer undergo surgery at some point during the course of their treatment. A primary operation may be undertaken for the purpose of confirming the diagnosis, staging, and debulking.

Full Article

BBY Ma

Hong Kong J Radiol 2011;14(Suppl):S31-6

It is now well recognised that patients with metastatic colorectal cancer represent heterogeneous subgroups of patients with differing prognoses, because of differences in the number and sites of metastases, performance status, and the types of prior treatment.

Full Article

RKC Ngan

Hong Kong J Radiol 2011;14(Suppl):S46-55

Adjuvant chemotherapy for node-positive breast cancers has evolved a long way from the time-honoured nonanthracycline regimen of six cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) to the historical standard of anthracycline-based regimens

Full Article

YL Kwong

Hong Kong J Radiol 2011;14(Suppl):S63-8

The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most Asian populations. Follicular lymphoma is generally considered to be indolent with a life expectancy of approximately 10 to 14 years.

Full Article

YL Wu

Hong Kong J Radiol 2011;14(Suppl):S77-83

The treatment paradigm of advanced non–small-cell lung carcinoma has evolved considerably owing to advances in molecular targeted therapy and the approval of two new classes of therapeutic agents, namely, epidermal growth factor receptor tyrosine-kinase inhibitors and angiogenesis inhibitors.